Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Operating Income (2021 - 2025)

Historic Operating Income for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.1 million.

  • InMed Pharmaceuticals' Operating Income rose 671.73% to -$2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.9 million, marking a year-over-year decrease of 16.84%. This contributed to the annual value of -$7.9 million for FY2025, which is 304.87% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Operating Income of -$2.1 million as of Q4 2025, which was up 671.73% from -$1.8 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Operating Income registered a high of -$485150.0 during Q2 2023, and its lowest value of -$6.5 million during Q2 2022.
  • For the 5-year period, InMed Pharmaceuticals' Operating Income averaged around -$2.5 million, with its median value being -$2.1 million (2025).
  • In the last 5 years, InMed Pharmaceuticals' Operating Income skyrocketed by 9255.9% in 2023 and then plummeted by 31929.53% in 2024.
  • InMed Pharmaceuticals' Operating Income (Quarter) stood at -$4.3 million in 2021, then surged by 48.66% to -$2.2 million in 2022, then increased by 25.7% to -$1.6 million in 2023, then crashed by 37.03% to -$2.3 million in 2024, then grew by 6.72% to -$2.1 million in 2025.
  • Its Operating Income was -$2.1 million in Q4 2025, compared to -$1.8 million in Q3 2025 and -$1.8 million in Q2 2025.